Boston-based Verve is a rare example of a gene-editing company targeting a disease that affects a large population, offering ...

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, accelerating a push into experimental cardiovascular therapies.

Zealand Pharma appoints Utpal Singh as CSO. TipRanks. Apr. 23, 2025, ... Most recently, he served as Senior Vice President of Small Molecule Discovery at Eli Lilly and Company .

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Dr. Matt Barnes, CSO and President of Nxera Pharma UK, commented: “We’re excited to have achieved this important milestone in this collaboration with Lilly, which marks a significant step ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.

Eli Lilly’s revenue has grown at an average annual rate of 17.4% over the past three years (vs. 6.2% for the S&P 500) Revenue rose 32.0% from $34 billion to $45 billion over the past year (vs. 5 ...

Positive results for Eli Lilly's new diabetes and weight-loss drug have recently boosted its stock price. Data from several studies on the GLP-1 drug are expected to come out this year. The ...

LUND, Sweden and INDIANAPOLIS, June 3, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) and Eli Lilly and Company ("Lilly") have entered a collaboration and license agreement, granting Lilly ...

Eli Lilly isn't done in developing new weight loss treatments. In fact, the best may still be to come, as it's working on a pill, which could be a game changer for the industry.